Organon Shareholders Approve $14/Share Sun Pharma Buyout with 98.7% Vote
OGN has more than doubled off its 52-week low of $5.69.
Summary
Organon shareholders overwhelmingly approved the $14.00 per share acquisition by Sun Pharma, with 98.7% of votes cast in favor. This clears a major hurdle for the $9.4 billion deal, which was announced in April and is expected to close by early 2027. The vote follows a lawsuit seeking to block the meeting, but the strong approval signals minimal dissent. The transaction still requires regulatory approvals, but the shareholder green light materially de-risks the path to completion. With the stock trading near its 52-week high of $13.60, the market is pricing in a high probability of closing.
At the time of this announcement, OGN was trading at $13.56 on NYSE in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $5.69 to $13.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Moneycontrol.